Research programme: ion channel blockers - Scion Pharmaceuticals

Drug Profile

Research programme: ion channel blockers - Scion Pharmaceuticals

Alternative Names: S-XX5; S-XX6; SPI 860

Latest Information Update: 29 Aug 2007

Price : $50

At a glance

  • Originator CeNeS Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Calcium channel antagonists; Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Atrial fibrillation; Neurological disorders; Neuropathic pain; Pain

Most Recent Events

  • 29 Aug 2007 No development reported - Preclinical for Pain in USA (unspecified route)
  • 29 Aug 2007 No development reported - Preclinical for Neuropathic pain in USA (unspecified route)
  • 29 Aug 2007 No development reported - Preclinical for Neurological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top